Switch theme
Sign up to access all valuation multiples
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
2005
394
LTM Revenue $216M
LTM EBITDA $9.8M
$840M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xeris Biopharma has a last 12-month revenue of $216M and a last 12-month EBITDA of $9.8M.
In the most recent fiscal year, Xeris Biopharma achieved revenue of $203M and an EBITDA of -$14.0M.
Xeris Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xeris Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $164M | $203M | XXX | XXX | XXX |
| Gross Profit | $87.6M | $135M | XXX | XXX | XXX |
| Gross Margin | 53% | 67% | XXX | XXX | XXX |
| EBITDA | -$23.7M | -$14.0M | XXX | XXX | XXX |
| EBITDA Margin | -14% | -7% | XXX | XXX | XXX |
| Net Profit | -$94.7M | -$62.3M | XXX | XXX | XXX |
| Net Margin | -58% | -31% | XXX | XXX | XXX |
| Net Debt | $65.1M | $123M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Xeris Biopharma's stock price is $4.
Xeris Biopharma has current market cap of $640M, and EV of $840M.
See Xeris Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $840M | $640M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Xeris Biopharma has market cap of $640M and EV of $840M.
Xeris Biopharma's trades at 3.9x LTM EV/Revenue multiple, and 85.3x LTM EBITDA.
Analysts estimate Xeris Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Xeris Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $840M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | -60.0x | XXX | XXX | XXX |
| P/E | -11.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -22.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpXeris Biopharma's NTM/LTM revenue growth is 29%
Xeris Biopharma's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Xeris Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Xeris Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Xeris Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 22% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 98% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xeris Biopharma acquired XXX companies to date.
Last acquisition by Xeris Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Xeris Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Xeris Biopharma founded? | Xeris Biopharma was founded in 2005. |
| Where is Xeris Biopharma headquartered? | Xeris Biopharma is headquartered in United States of America. |
| How many employees does Xeris Biopharma have? | As of today, Xeris Biopharma has 394 employees. |
| Who is the CEO of Xeris Biopharma? | Xeris Biopharma's CEO is Mr. John P. Shannon. |
| Is Xeris Biopharma publicy listed? | Yes, Xeris Biopharma is a public company listed on NAS. |
| What is the stock symbol of Xeris Biopharma? | Xeris Biopharma trades under XERS ticker. |
| When did Xeris Biopharma go public? | Xeris Biopharma went public in 2018. |
| Who are competitors of Xeris Biopharma? | Similar companies to Xeris Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Xeris Biopharma? | Xeris Biopharma's current market cap is $640M |
| What is the current revenue of Xeris Biopharma? | Xeris Biopharma's last 12-month revenue is $216M. |
| What is the current EBITDA of Xeris Biopharma? | Xeris Biopharma's last 12-month EBITDA is $9.8M. |
| What is the current EV/Revenue multiple of Xeris Biopharma? | Current revenue multiple of Xeris Biopharma is 3.9x. |
| What is the current EV/EBITDA multiple of Xeris Biopharma? | Current EBITDA multiple of Xeris Biopharma is 85.3x. |
| What is the current revenue growth of Xeris Biopharma? | Xeris Biopharma revenue growth between 2023 and 2024 was 24%. |
| Is Xeris Biopharma profitable? | Yes, Xeris Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
